Cosette M Wheeler
Overview
Explore the profile of Cosette M Wheeler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
166
Citations
7631
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Webster E, Seiger K, Core S, Collar A, Knapp-Broas H, Graham J, et al.
Vaccines (Basel)
. 2022 Jan;
10(1).
PMID: 35062772
An effective vaccine against is urgently needed as infection rates continue to rise and causes reproductive morbidity. An obligate intracellular pathogen, employs a type 3 secretion system (T3SS) for host...
12.
Landy R, Mathews C, Robertson M, Wiggins C, McDonald Y, Goldberg D, et al.
Gynecol Oncol
. 2021 Oct;
163(3):614.
PMID: 34602285
No abstract available.
13.
Banila C, Lorincz A, Scibior-Bentkowska D, Clifford G, Kumbi B, Beyene D, et al.
Int J Cancer
. 2021 Sep;
150(2):290-302.
PMID: 34562270
The shift towards primary human papillomavirus (HPV)-based screening has necessitated the search for a secondary triage test that provides sufficient sensitivity to detect high-grade cervical intraepithelial neoplasia (CIN) and cancer,...
14.
Castle P, Kinney W, Chen L, Kim J, Jenison S, Rossi G, et al.
J Natl Cancer Inst
. 2021 Aug;
PMID: 34463763
In 2012, national recommendations for cervical-cancer screening of women aged 30-64 years were quinquennial human papillomavirus and cytology co-testing or triennial cytology. Data from a state-wide surveillance program in New...
15.
Perkins R, Adcock R, Benard V, Cuzick J, Waxman A, Howe J, et al.
Prev Med
. 2021 Aug;
153:106770.
PMID: 34416221
Failure to follow-up women after abnormal cervical screening could lead to cervical cancers, yet little is known about adherence to recommended follow-up after abnormal co-testing [cytology and high-risk human papillomavirus...
16.
Hernandez-Lopez R, Hermosillo L, Leon-Maldonado L, Velazquez-Cruz R, Torres-Ibarra L, Lazcano-Ponce E, et al.
PLoS One
. 2021 Jul;
16(7):e0254946.
PMID: 34288949
Introduction: Urine self-sampling for human papillomavirus (HPV)-based cervical cancer screening is a non-invasive method that offers several logistical advantages and high acceptability, reducing barriers related to low screening coverage. This...
17.
Cuzick J, Du R, Adcock R, Kinney W, Joste N, McDonald R, et al.
Gynecol Oncol
. 2021 Jul;
162(3):555-559.
PMID: 34253387
Objectives: Human papillomavirus (HPV) testing for cervical screening has been shown to increase the yield of precancerous disease and reduce the incidence of cervical cancer more than cytology alone. Here...
18.
Hammer A, Gravitt P, Adcock R, Patterson N, Cuzick J, Wheeler C
Sex Transm Dis
. 2021 May;
48(12):e186-e189.
PMID: 33993157
In this population-based US study, the overall prevalence of Mycoplasma genitalium was 1.95% (95% confidence interval [CI], 1.62%-2.34%), declining from 6.12% (95% CI, 4.72%-7.92%) in women aged 21 to 24...
19.
Landy R, Mathews C, Robertson M, Wiggins C, McDonald Y, Goldberg D, et al.
Gynecol Oncol
. 2021 Apr;
161(3):913.
PMID: 33867145
No abstract available.
20.
Torres-Ibarra L, Lorincz A, Wheeler C, Cuzick J, Hernandez-Lopez R, Spiegelman D, et al.
Int J Cancer
. 2020 Nov;
148(9):2264-2273.
PMID: 33252834
High-risk human papillomavirus type 16/18 (HPV16/18) genotyping is unable to accurately discriminate nonprogressive infections from those that will progress to cervical cancer. Our study aimed to assesses if additional testing...